123 results
8-K
EX-99.1
ABBV
Abbvie Inc
26 Apr 24
AbbVie Reports First-Quarter 2024 Financial Results
7:43am
(atogepant) to prevent chronic and episodic migraine. The overall long-term safety results were consistent with the known safety profile of Qulipta … in chronic and episodic migraine, and no new safety signals were identified. These results also support improvements in key efficacy outcomes, including
424B5
ABBV
Abbvie Inc
26 Feb 24
Prospectus supplement for primary offering
6:12am
(moderate to severe)
North America, European Union
Plaque psoriasis (moderate to severe chronic)
North America, European Union
Juvenile idiopathic arthritis … separate designations. Imbruvica currently is approved for the treatment of adult patients with blood cancers such as chronic lymphocytic leukemia (“CLL
424B5
kn9cqc
21 Feb 24
Prospectus supplement for primary offering
8:39am
8-K
EX-99.1
qbl6w7477 xmajul6
27 Oct 23
AbbVie Reports Third-Quarter 2023 Financial Results
7:49am
8-K
EX-99.1
uwr2m lgv47fp1s
27 Jul 23
AbbVie Reports Second-Quarter 2023 Financial Results
7:45am
8-K
EX-99.1
95awbdyblz4a1x l68
27 Apr 23
AbbVie Reports First-Quarter 2023 Financial Results
7:36am
8-K
EX-99.1
zwvaavurs
28 Oct 22
AbbVie Reports Third-Quarter 2022 Financial Results
7:48am
8-K
EX-99.1
7hd48w
29 Jul 22
AbbVie Reports Second-Quarter 2022 Financial Results
7:49am
8-K
EX-99.1
mzpm av6vh927nwph
29 Apr 22
AbbVie Reports First-Quarter 2022 Financial Results
9:00am
8-K
EX-99.1
gu5 0ggotv34
29 Apr 22
AbbVie Reports First-Quarter 2022 Financial Results
7:45am